SSAT046 Addition of Maraviroc to monotherapy Darunavir/Ritonavir study

Registry ID

EUCTR2012-000649-11

Source registry

EUCTR

Status

Completed

Phase

PHASE4

Sponsor

St Stephen's Aids Trust

Start date

2012-04-30

Completion date

2015-11-19

Last update

2026-08-16

Conditions

• HIV infection
• HIV

Summary

To investigate changes from week 12 to week 36 in levels of inflammation within the fluid that surrounds the Central Nervous System, called cerebrospinal fluid or CSF, when maraviroc is taken along with regular darunavir/ritonavir monotherapy for 24 weeks.

Locations

• , , UK
• , , Spain

Related clinical trials

• A pilot, randomized, open-label, non-active comparator controlled clinical trial to evaluate the effects of letermovir prophylaxis on T-cell immune activation in participants with treated HIV-1 Infection
• A Patient-Oriented Research Mentoring Program in Tobacco Dependence and Implementation Science Research
• Streamlining Telehealth for Expanded PrEP Utilization Through Community Partnerships
• Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption
• Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
• Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants

View on source registry